Safety and Efficacy of the ACE-Inhibitor Ramipril in Alport Syndrome: The Double-Blind, Randomized, Placebo-Controlled, Multicenter Phase III EARLY PRO-TECT Alport Trial in Pediatric Patients
Table 1
Alport syndrome levels describing renal damage and loss of function.
Stage
Definition
0
Microhaematuria without microalbuminuria (usually at birth)
I
Microalbuminuria (30–300 mg albumin/gCrea)
II
Proteinuria >300 mg albumin/gCrea
III
>25% decline of normal renal function (creatinine clearance)
